BCHE and Alzheimer disease: It evolves cognitive abilities in normal and AD patients by inhibiting the BChE enzyme, however, it is now clinically not in use. Rivastigmine, a synthetic analog of physostigmine, has been reported to be therapeutically successful and has dual-action AChE- and BChE-inhibitory properties in clinical studies